EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis

SGLT2-Inhibitoren reduzieren das epikardiale Fettgewebe stärker als GLP-1-Agonisten oder Bewegungsinterventionen bei Patient:innen mit Typ-2-Diabetes mellitus und/oder Adipositas: systematische Übersicht und Network-Metaanalyse

Yu Bao iD, Yucai Hu, Menglong Shi, Zhiqiang Zhao

Diabetes, Obesity and Metabolism · 2025-03 · 27 (3) · 1096-1112

DOI: 10.1111/dom.16107 ↗

Auf einen Blick

16 Studien mit 867 Personen: SGLT2-Inhibitoren senkten die Dicke des epikardialen Fettgewebes stärker als Placebo, GLP-1-Agonisten und konventionelle antidiabetische Therapie.

Fragestellung

Wie wirken SGLT2-Inhibitoren, GLP-1-Agonisten und Bewegung auf die Dicke des epikardialen Fettgewebes und auf Parameter des Glukose-Lipid-Stoffwechsels bei T2DM und/oder Adipositas?

Methode

Systematische Übersicht und Network-Metaanalyse von RCTs und einer Fall-Kontroll-Studie; Suche in PubMed, EMBASE, Cochrane Library und Web of Science bis 31. Januar 2024.

Ergebnisse

16 Studien (15 RCTs, 1 Fall-Kontroll-Studie) mit 867 Personen. SGLT2-Inhibitoren senkten EAT gegenüber Placebo (SMD −0,85 cm; 95 %-KI −1,39 bis −0,31), GLP-1-Agonisten (SMD −0,74 cm; 95 %-KI −1,45 bis −0,02) und konventioneller Therapie (SMD −1,69 cm; 95 %-KI −2,38 bis −0,99).

Schlussfolgerung der Autor:innen

SGLT2-Inhibitoren hatten einen klaren Vorteil gegenüber Placebo und anderen Therapien bei der Senkung der EAT-Dicke und sollten priorisiert werden.

Kernaussagen

  • EAT: SGLT2-Inhibitoren besser als Placebo, GLP-1-Agonisten und konventionelle Therapie
  • BMI und HbA1c sanken unter SGLT2-Inhibitoren gegenüber Placebo
  • Keine signifikanten Unterschiede für Gesamtcholesterin, LDL- und HDL-Cholesterin

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 06.12.2024. Verfasst von Yu Bao und 3 weiteren Autor:innen. Beteiligte Einrichtung: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Obesity, Adipose Tissue. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Education Department of Henan Province.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epicardial adipose tissue (EAT) plays a significant role in several cardiovascular diseases. As a correctable risk factor and potential therapeutic target, reducing EAT has multiple cardiovascular benefits, especially in those with abnormal glucolipid metabolism. The objective of this research was to compare the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide‐1 (GLP‐1) agonists, and exercise on the thickness of EAT and indicators of glucolipid metabolism in people with type 2 diabetes mellitus (T2DM), obesity, and T2DM with obesity.

Methods

We searched four electronic databases: PubMed, EMBASE, the Cochrane Library, and Web of Science for articles before 31 January 2024, regardless of language. We included randomized controlled trials and a small number of case–control studies in this network meta‐analysis. Differences in mean changes in EAT, body mass index, and glucolipid metabolism‐related metrics were assessed.

Results

A comprehensive analysis was conducted on 16 trials (15 randomized controlled trials and one case–control study), comprising a total of 867 people. SGLT2 inhibitors were significantly better at reducing EAT than placebo (standard mean different [SMD] = −0.85 cm [95% confidence interval (CI) −1.39, −0.31]); a similar result was observed for exercise compared with placebo (SMD = −0.78 cm [95% CI −1.37, −0.18]). SGLT2 inhibitors were also significantly better at reducing EAT than GLP‐1 agonists and conventional hypoglycaemic therapy (e.g., metformin or insulin; SMD = −0.74 cm [95% CI −1.45, −0.02] and SMD = −1.69 cm [95% CI −2.38, −0.99], respectively). SGLT2 inhibitors were significantly better than placebo at reducing body mass index (MD = −0.90 kg/m 2 [95% CI −1.14, −0.66]) and glycosylated haemoglobin (MD = −0.52% [95%CI −0.86, −0.18]). A similar result was observed when comparing GLP‐1 agonists and placebo (MD = −0.48% [95% CI −0.93, −0.03]). Changes in total cholesterol, low‐density lipoprotein cholesterol, and high‐density lipoprotein cholesterol were not statistically significant between interventions.

Conclusion

SGLT2 inhibitors have a distinct advantage over both placebo and other therapies at lowering EAT thickness, a result supported by direct comparisons and surface under the cumulative ranking curve analysis. Therefore, SGLT2 inhibitors should be prioritized as a treatment to reduce EAT in individuals with aberrant glucolipid levels, such as patients with T2DM and/or obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsObesityAdipose TissuePericardiumExercise TherapyHumansGlucagon-Like Peptide-1 Receptor AgonistsRandomized Controlled Trials as TopicGlucagon-Like Peptide 1Epicardial Adipose Tissue

Stichwörter der Autor:innen

EAT thicknessGLP‐1 agonistsSGLT‐2 inhibitorsexercise

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
  • Department of Cardiovascular Diseases, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
  • Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Tianjin University of Traditional Chinese Medicine, Tianjin, China.

ORCID-Profile: Yu Bao

Förderung

  • Education Department of Henan Province

Zitieren

APA

Bao, Y., Hu, Y., Shi, M., & Zhao, Z. (2025). SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism, 27(3), 1096-1112. https://doi.org/10.1111/dom.16107

Vancouver

Bao Y, Hu Y, Shi M, Zhao Z. SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism. 2025;27(3):1096-1112. doi:10.1111/dom.16107

BibTeX
@article{Bao2025,
  author = {Bao, Yu and Hu, Yucai and Shi, Menglong and Zhao, Zhiqiang},
  title = {SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {1096--1112},
  doi = {10.1111/dom.16107}
}
Kostenlos starten →